Crystal structure of the human NK<sub>1</sub> tachykinin receptor.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 30538204.
- Also identified by DOI 10.1073/pnas.1812717115 and PMC identifier 6310836.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The NK<sub>1</sub> tachykinin G-protein-coupled receptor (GPCR) binds substance P, the first neuropeptide to be discovered in mammals. Through activation of NK<sub>1</sub>R, substance P modulates a wide variety of physiological and disease processes including nociception, inflammation, and depression. Human NK<sub>1</sub>R (hNK<sub>1</sub>R) modulators have shown promise in clinical trials for migraine, depression, and emesis. However, the only currently approved drugs targeting hNK<sub>1</sub>R are inhibitors for chemotherapy-induced nausea and vomiting (CINV). To better understand the molecular basis of ligand recognition and selectivity, we solved the crystal structure of hNK<sub>1</sub>R bound to the inhibitor L760735, a close analog of the drug aprepitant. Our crystal structure reveals the basis for antagonist interaction in the deep and narrow orthosteric pocket of the receptor. We used our structure as a template for computational docking and molecular-dynamics simulations to dissect the energetic importance of binding pocket interactions and model the binding of aprepitant. The structure of hNK<sub>1</sub>R is a valuable tool in the further development of tachykinin receptor modulators for multiple clinical applications.
Medical subject headings
- Morpholines
- Receptors, Neurokinin-1
- Substance P